December 30, 2014 Synthetic Biologics Announces First Patient Dosed in Phase 1b Clinical Trial of SYN-004 for the Prevention of C. difficile Infection
December 22, 2014 Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection
December 2, 2014 Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection
November 24, 2014 Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection
November 14, 2014 Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights
October 22, 2014 Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program
October 15, 2014 Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board
September 16, 2014 Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
